{"id":36649,"date":"2019-09-30T08:39:25","date_gmt":"2019-09-30T08:39:25","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=36649"},"modified":"2019-09-30T13:11:44","modified_gmt":"2019-09-30T13:11:44","slug":"sctoland-approves-dual-therapy-with-dolutegravir-lamivudine-dovato","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/36649","title":{"rendered":"Scotland approves dual therapy with dolutegravir\/lamivudine (Dovato)"},"content":{"rendered":"

Simon Collins, HIV i-Base<\/span><\/strong><\/p>\n

On 9 September 2019 the Scottish Medicines Consortium (SMC) issued positive advice for<\/span>\u00a0<\/span><\/span>dolutegravir\/lamivudine (Dovato), making this option immediately available in Scotland.<\/span><\/strong><\/p>\n

The indication is for adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to integrase inhibitors, or lamivudine.<\/span><\/p>\n

It is a two-drug fixed-dose combination (FDC) manufactured by ViiV Healthcare with the trade name Dovato.<\/span><\/p>\n

comment<\/span><\/h3>\n

The rapid evaluation of new medicines by the SMC is a model that should be just as easy to adopt across the UK – especially when the price ensures there are no new cost pressures on the NHS.<\/span><\/strong><\/p>\n

Dovato was approved in the US in April 2019 and in the EU in July 2019 as initial ART based on GEMINI 1 and 2 studies.<\/span><\/strong><\/p>\n

At IAS 2019, the phase 3 TANGO study reported dolutegravir\/lamivudine was non-inferior as a switch option compared to people remaining on TAF-based triple ART. [2]<\/strong><\/p>\n

Reference<\/span><\/p>\n

    \n
  1. ViiV press release. Positive SMC decision enables the first UK patients to access Dovato(dolutegravir\/lamivudine), a 2-drug regimen, once-daily, single-pill for the treatment of HIV. (9 September 2019).
    \n<\/span>https:\/\/www.scottishmedicines.org.uk\/medicines-advice\/dolutegravir-lamivudine-dovato-abbreviated-smc2205\/<\/a><\/li>\n
  2. Switching to dolutegravir\/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study. HTB July 2019.
    \n<\/u>    https:\/\/i-base.info\/htb\/36450<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Simon Collins, HIV i-Base On 9 September 2019 the Scottish Medicines Consortium (SMC) issued positive advice for\u00a0dolutegravir\/lamivudine (Dovato), making this option immediately available in Scotland. The indication is for adults and adolescents above 12 years of age weighing at least …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,38],"tags":[],"class_list":["post-36649","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=36649"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/36649\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=36649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=36649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=36649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}